Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.44 |
| ▸ | TYR | P14679 | 5/20 | 0.43 |
| ▸ | CPB1 | P15086 | 5/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.42 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7001068 | 1.00 | SLC7A5 (0.44) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL4727798 | 0.88 | CYP1A2 (0.45) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL4726518 | 0.88 | CYP1A2 (0.45) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL358922 | 0.87 | CYP1A2 (0.44) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL3808000 | 0.86 | CPB2 (0.42) | CYP1A2CPB2CPB1GRIA1GRIA2 | |
| SCHEMBL18074129 | 0.86 | CPB2 (0.42) | CYP1A2CPB2CPB1GRIA1GRIA2 | |
| Hydrochloric Acid SCHEMBL14831326 | 0.85 | CYP1A2 (0.43) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL52216 | 0.83 | CYP2C9 (0.47) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL52215 | 0.83 | CYP2C9 (0.47) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL163222 | 0.83 | CYP2C9 (0.47) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2769990-A2 | Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY | Domantis Limited (GB) | 2014-08-27 | — | — | EP | disclosed |
| US-8603972-B2 | Extended GLP-1 compounds | NOVO NORDISK A/S (DK) | 2013-12-10 | — | — | US | disclosed |
| CN-101128487-B | Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY | DOMANTIS LTD | 2012-10-10 | — | — | CN | disclosed |
| US-20090214534-A1 | Bispecific Domain Antibodies Targeting Serum Albumin And GLP-1 Or PYY | DOMANTIS LIMITED (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20080207507-A1 | Extended Glp-1 Compounds | NOVO NORDISK A/S (DK) | 2008-08-28 | — | — | US | disclosed |
| CN-101128487-A | Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY | DOMANTIS LTD (GB) | 2008-02-20 | — | — | CN | disclosed |
| EP-1841796-A2 | BISPECIFIC DOMAIN ANTIBODIES TARGETING SERUM ALBUMIN AND GLP-1 OR PYY | Domantis Limited (GB) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006059106-A2 | BISPECIFIC DOMAIN ANTIBODIES TARGETING SERUM ALBUMIN AND GLP-1 OR PYY | DOMANTIS LIMITED (GB) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207507-A1 | Extended Glp-1 Compounds | GLP1R, GIPR, IAPP | SLC7A5 1333/4885ALPI 815/4885PKM 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.